Drugs giants must help to solve the antibiotics crisis
Commenting in the Times, Tim Jinks, head of the drug-resistant infections priority programme at the Wellcome Trust, highlights the need for change in how we value and reimburse antibiotics.
Tim Jinks looks at the prospects for new antibiotic treatments given today's fragile antibiotic market:
The broken global market for antibiotics and the failure of governments to give it the overhaul it badly needs has meant that many big pharmaceutical companies have either left the field altogether or disinvested.
The commentary compares the 2020 AMR Benchmark to reports issued previously by the World Health Organization, which reached similar conclusions about the overall lack of private investment and innovation in antibiotic development.